Main Uses and Symptomatic Benefits

This medication is commonly used for managing pain associated with spasmodic states and conditions like primary dysmenorrhea. These applications extend to therapeutic areas involving the gastrointestinal and urogenital tracts. It is applied across domains where additional symptomatic support is needed for symptoms related to physical discomfort that may appear suddenly or intensify over time.

Espasmo Dologinex is relevant for managing symptom clusters that interfere with daily comfort, such as those that create noticeable physiological strain. It is commonly used across conditions characterized by periods of heightened symptoms or recurrent manifestations, where short-term symptomatic assistance is needed. The medication supports patients during difficult episodes by easing the overall symptom burden and assists with supporting functional stability when symptoms fluctuate. As a general description of its function, “It offers symptomatic relief that helps patients cope more steadily with difficult episodes.”

---

Quick Fact: Relief for Physical Discomfort

Regulatory References

1. CECMED official product information

Eligibility Map: Who Can and Cannot Use Espasmo Dologinex

This section outlines the eligibility criteria and official contraindications for Espasmo Dologinex, based strictly on government regulatory documentation for this fixed-dose combination (typically Propinox plus an analgesic/NSAID component).

---

Populations for Whom Use is Prohibited (Contraindications)

Espasmo Dologinex must not be used in individuals with the following conditions or states:

• Hypersensitivity: Known allergy to Propinox Hydrochloride, the analgesic component, or any other ingredients.
• Organ Failure: Severe impairment of liver (hepatic) or kidney (renal) function.
• Gastrointestinal Conditions: Active gastroduodenal ulcer, recurrent gastrointestinal bleeding, or ulcerative colitis.
• Obstructive Disorders: Conditions causing physical blockages, such as intestinal or urinary obstruction and megacolon.
• Specific Eye/Muscle/Prostate Issues: Narrow-angle glaucoma, myasthenia gravis, or significant prostatic hypertrophy.
• Age: Children under 12 years of age.
• Physiological States: Pregnancy and lactation (breastfeeding).

---

Populations Requiring Restricted Use

Use is restricted and requires careful evaluation and monitoring in patients with a history of hypertension or mild to moderate heart failure, as well as in the elderly population due to increased risk of adverse effects.

Note: Eligibility is primarily established for adults and children over 12 years of age who do not present with any of the stated contraindications.

Interactions with other medicines and products

This medication contains components that may interact with several drug classes, necessitating specific management or close monitoring.

Documented Interactions

Interacting Product Category	Practical Implication
Anticoagulants (e.g., Warfarin) and Antiplatelet agents (e.g., Aspirin)	Increased risk of serious bleeding. Co-administration generally requires intensive monitoring and/or dose adjustments.
Other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)	Significant increase in the risk of gastrointestinal adverse effects, including bleeding. Concurrent use is generally not recommended.
Antihypertensive drugs (e.g., ACE inhibitors, Diuretics)	Potential for reduced effectiveness of the blood pressure-lowering medicine, requiring blood pressure monitoring.
Lithium and Methotrexate	Increased plasma concentrations of Lithium and Methotrexate due to reduced renal clearance. Monitoring of drug levels is required.
Other Anticholinergic drugs	Additive anticholinergic effects may occur, such as increased risk of blurred vision and constipation.
SSRIs/SNRIs	Increased risk of bleeding when co-administered.

Clinical Considerations

The interaction profile is dominated by the Non-Steroidal Anti-Inflammatory Drug (NSAID) component, which primarily carries the risk of bleeding and gastrointestinal harm in combination with related agents. The anticholinergic component contributes to interactions resulting in enhanced parasympathetic nervous system effects. The use of this medicine with any of the listed products should follow the strict guidance provided by official healthcare information, including necessary monitoring and constraints on co-administration.

How Espasmo Dologinex Works

The drug's mechanism is based on the complementary actions of its two components: Clonixin and Pargeverine. The combined mechanism targets both the eicosanoid pathway and the smooth muscle contraction cascade.

Enzyme Inhibition to Modulate Eicosanoid Signaling

Clonixin acts within the inflammatory signaling domain by performing a non-selective inhibition of the Cyclooxygenase (COX) enzymes. This molecular action modifies the arachidonic acid cascade, significantly reducing the synthesis of prostaglandins. The physiological consequence of this enzyme inhibition is the decrease in the sensitization of peripheral pain fibers, resulting in a modulation of pain signal propagation.

Dual-Action Visceral Smooth Muscle Relaxation

Pargeverine engages the mechanisms regulating visceral smooth muscle tone via two pathways. Firstly, it employs a musculotropic blockade of the L-type Ca^2+ channels, directly limiting the influx of calcium ions required for muscle contraction. Secondly, it acts as a competitive antagonist at the Muscarinic Acetylcholine Receptors (mAChRs), blocking the neurogenic signals that stimulate smooth muscle tone. The resulting physiological effect is the active induction of muscle relaxation; this process is termed spasmolysis.

The synergistic engagement of these two domains is central to the drug's combined mechanism, resulting in a comprehensive physiological influence over both pathways.

Espasmo Dologinex is intended exclusively for oral administration as a fixed-dose coated tablet, combining 125.0 mg of Clonixin and 10.0 mg of Pargeverine per unit. The primary route of administration is by swallowing the tablet whole.

Administration Guidelines

The usage protocol for this medicine is characterized as symptomatic and short-term, restricted to periods when painful muscle spasms are present. It is not intended for continuous or long-term therapeutic maintenance.

Instruction	Detail
Route of administration	Oral, as a whole coated tablet.
Dosing schedule	Adults and adolescents over 12 years: Typically one to two coated tablets per dose.
Frequency pattern	Intermittent use, with a required interval of 6 to 8 hours between each dose.
Age-group rules	Approved for use in adults and pediatric patients over 12 years of age.

Procedural Structure

The clinical instruction defines the use of Espasmo Dologinex as a demand-based oral intervention. The standard dose should be administered when needed for acute symptoms, ensuring the strict observation of the 6-to-8-hour minimum interval before any subsequent dose is taken. Administration should be discontinued once the acute symptomatic episode has resolved, adhering to its designation as a short-term treatment.

Research evidence / Overview of Studies for Espasmo Dologinex

Evidence for Spastic Pain Relief

Research exploring the general use of this combination medicine has involved clinical data submitted to regulatory bodies. These studies was evaluated in research contexts involving fluctuating or unstable symptoms where pain was associated with involuntary smooth muscle contractions. Research highlights that the combination was observed to describe patterns of change in patient-reported experiences. The clinical findings were used in the regulatory review for this general indication. However, specific details on the randomized controlled trials, such as the exact size of the study populations or the precise follow-up durations, are not fully established in all publicly available summaries related to the general indication.

Evidence for Primary Dysmenorrhea

The research base for use in primary dysmenorrhea includes more specific investigations, such as randomized, double-blind, placebo-controlled crossover trials. These studies were conducted on adult women experiencing primary dysmenorrhea, focusing on outcomes capturing phases of heightened symptom activity linked to menstruation. Findings indicate patterns related to measured pain intensity outcomes compared to baseline measurements. The evidence contributes to understanding episodic or acute changes associated with the condition. The results of these trials are relevant in studies assessing short-term or episodic symptom patterns during the initial days of menstruation.

Long-term Follow-up and Durability of Symptom Control

Research exploring continuous use of medications in the antispasmodic class, such as Pargeverine, typically limits treatment duration due to the focus on acute, short-term relief. For this reason, follow-up durations were limited in many of the core efficacy studies, which was observed in trials assessing short-term or episodic symptom patterns. Long-term effects are not fully established for this combination, as research primarily monitors outcomes related to episodic or acute changes. Therefore, limited information for long-term outcomes or the durability of symptomatic control beyond short-term use is available.

Research in Specific Patient Groups and Remaining Gaps

The key randomized controlled trials that inform the use of this medicine were conducted on general adult populations, typically spanning ages 18 to 65. Consequently, the results apply only to the populations studied. Data for certain groups remain insufficient, including research exploring outcomes in older adults, children, or populations presenting with significant comorbidities. Furthermore, comparative evidence is lacking against all available alternative therapeutic options for spasmodic pain and dysmenorrhea, meaning research does not determine whether an individual will respond similarly.

Common questions about Espasmo Dologinex (FAQ)

Q: Is Espasmo Dologinex recommended for long-term or chronic pain management?

According to the official product information, this medication is designed for short-term symptomatic relief only. It is not intended for continuous or long-term therapeutic maintenance. Its use is defined as short-term and restricted to periods when painful muscle spasms are present.

Q: What serious side effects should I be aware of when taking this drug?

Regulatory safety data notes that serious adverse reactions can occur, although often rarely. These documented risks include events such as gastrointestinal bleeding, the inability to urinate (urinary retention), and a significant increase in intraocular pressure (pressure within the eye).

Q: How should I dispose of any unused or expired tablets?

Official labeling instructs that this product should be disposed of according to standard local pharmaceutical waste guidelines. This ensures that the medicine is handled safely and does not pose a risk to the environment or others. Specific local requirements can often be confirmed by consulting a pharmacist or local waste management resources.

Q: Does Espasmo Dologinex help relieve period pain (primary dysmenorrhea)?

Official studies and clinical investigations submitted to regulatory authorities include research on the use of this combination medicine in women experiencing primary dysmenorrhea (period pain). This evidence contributes to understanding its effect on acute symptoms linked to menstruation.

Q: What should I do if I miss a scheduled dose?

The administration guidelines state that if a dose is missed, any subsequent dose should only be taken after the required minimum time interval has passed. The use of the medicine is defined as a demand-based intervention with a strict interval observation.

Q: Does the drug contain any common allergens like lactose or gluten?

Regulatory documents require a full listing of all active and inactive ingredients, known as excipients. The presence of these components is detailed in the official 'List of Excipients' on the product label, which should be reviewed for specific allergy information.

Q: What is the maximum number of tablets I can take in a 24-hour period?

The official administration protocol requires a specific minimum interval between doses. Based on this required interval, the total quantity of tablets taken in a 24-hour period should not exceed the amount consistent with the shortest permissible interval defined in the official dosing schedule.

How to Store and Dispose of Espasmo Dologinex?

The storage and disposal instructions for Espasmo Dologinex are established by regulatory agencies to ensure product stability and safety. These requirements define the specific environmental conditions and shelf-life of the medicine.

---

Official Storage and Stability

Requirement	Official Instruction
Temperature	Store below 30 C (86 F)
Packaging	Must remain in its original commercial packaging (PVC/AL blisters)
Shelf-Life	Has an established validity period of 24 months

---

Disposal Requirements

Official labeling does not provide specific mandatory instructions for the destruction of non-usable or expired product remnants. Therefore, the product should be disposed of according to standard local pharmaceutical waste guidelines.